Evidence for Hox and E2A–PBX1 collaboration in mouse T-cell leukemia
Using murine Moloney leukemia virus (MMLV)-based proviral insertional mutagenesis, we previously showed a preferential targeting of a small region in the Hoxa gene locus in E2A–PBX1 -induced lymphoid leukemia resulting in the overexpression of several Hoxa genes including Hoxa10 , Hoxa9 and Hoxa7. T...
Gespeichert in:
Veröffentlicht in: | Oncogene 2008-10, Vol.27 (49), p.6356-6364 |
---|---|
Hauptverfasser: | , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Using murine Moloney leukemia virus (MMLV)-based proviral insertional mutagenesis, we previously showed a preferential targeting of a small region in the
Hoxa
gene locus in
E2A–PBX1
-induced lymphoid leukemia resulting in the overexpression of several
Hoxa
genes including
Hoxa10
,
Hoxa9
and
Hoxa7.
This observation suggested a functional interaction between
Hox
gene overexpression and
E2A–PBX1
in lymphoid tumors. To further explore this possibility, we generated a series of compound
E2A–PBX1
×
Hox
transgenic mice and tested the genetic interaction between these genes in the generation of lymphoid leukemia
in vivo
. Results presented in this report show that the onset of T-cell leukemia is significantly accelerated in
E2A–PBX1
×
Hoxb4
compound transgenic animals when compared with control
E2A–PBX1
or
Hoxb4
littermates.
Hoxa9
appears less potent than
Hoxb4
to accelerate
E2A–PBX1
-induced T-cell leukemia in mice.
E2A–PBX1-
induced T-cell leukemias express much higher levels of
Hoxa
genes than MMLV-induced counterparts, possibly suggesting a contribution of these genes to T-cell transformation by
E2A–PBX1
. Collectively, these data provide the first genetic evidence showing oncogenic collaboration between
E2A–PBX1
and a
Hox
gene in lymphoid malignancies
in vivo
and document the specific deregulation of a subgroup of
Hoxa
genes in these leukemias. |
---|---|
ISSN: | 0950-9232 1476-5594 |
DOI: | 10.1038/onc.2008.233 |